Summary
A rapid expansion of our knowledge of drugs that intervene with human immunodeficiency virus (HIV) infection has taken place. This review covers known and potential anti-HIV targets, including receptor blocking agents, membrane stabilisers, reverse transcriptase inhibitors and chain terminators, RNases, agents altering activation, assembly, budding or regulation of transcription and translation, post-transcriptional modifications and other areas. Important or promising agents, such as zidovudine (ZVD; azidothymidine, AZT), dideoxycytidine, dideoxyinosine, foscarnet, interferons, imuthiol, isoprinosine and others that are either on the market or in advanced clinical trials are emphasised.
Four years after the discovery of the aetiological agent, the first drug, zidovudine, has been registered. Many questions about this drug remain, however, owing to the haste with which it was developed. An unprecedented number of other compounds are under evaluation, making it difficult to assess the relative merits of the different compounds and thus set priorities for their development The point has been reached where a better economical and intellectual framework is necessary so that researchers and physicians are not over-whelmed by the difficulties of conducting clinical trials during the epidemic and have a reasonable chance of keeping up with laboratory developments.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abrams D, Gottlieb MS, Grieco M, Speer M, Bernstein S (Eds). AIDS/HIV Experimental treatment directory, Vol. 2, No. 2, American Foundation for AIDS Research (AmFAR), 1988
Abrams DI, Kuno S, Wong R, Jeffords K, Nash M, et al. Oral dextran sulphate (UA001) in the treatment of acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Annals of Internal Medicine 110: 183–188, 1989
Ahluwalia G, Cooney DA, Mitsuya H, Fridland A, Flora ZH, et al. Initial studies on the cellular pharmacology of 2′,3′- dideoxyinosine an inhibitor of HIV infectivity. Biochemical Pharmacology 36: 3797–3800, 1987
Anand R, Moore J, Feorino P, Curran J, Srinivasan A. Rifabutine inhibits HTLV-III. Lancet 1: 97–98, 1986
Andrieu J-M, Even P, Venet A, Tourani J-M, Stern M, et al. Effects of cyclosporin on T-cell subsets in human immunodeficiency disease. Clinical Immunology and Immunopathology 47: 181–198, 1988
Arora SK. Correlation of structure and activity of ansamycins: molecular structure of sodium rifamycin SV. Molecular Pharmacology 23: 133–140, 1983
Ayers KM. Preclinical toxicology of zidovudine. American Journal of Medicine 85: 186–188, 1988
Baba M, Pauwels R, Balzarini J, Arnout J, Demyter J, et al. Mechanism of inhibitory effect of dextran sulphate and heparin on replication of human immunodeficiency virus in vitro. Proceedings of the National Academy of Sciences USA 85: 6132–6136, 1988
Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clercq E, et al. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′- dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrobial Agents and Chemotherapy 31: 1613–1617, 1987
Bach MC. Possible drug interaction during therapy with azidothymidine and acyclovir for AIDS. New England Journal of Medicine 316: 547, 1987
Balzarini J, Baba M, Pauwels R, Herdewijn P, Clercq E. Antiretro virus activity of 3′fluoro- and 3′-azido-substituted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochemical Pharmacology 37: 2847–2856, 1988
Balzarini J, Mitsuya H, De Clercq E, Broder S. Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV III)/lymphadenopathy associated virus (LAV). International Journal of Cancer 37: 451–457, 1986
Balzarini J, Naeses L, Herdewijn P, Rosenberg I, Holy A, et al. Marked in vivo antiretrovirus activity of 9-(2-phosphonyl-methoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proceedings of the National Academy of Sciences 86: 332–336, 1989
Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220: 868–871, 1983
Bazin H, Chattopadhaya J, Datema R, Ericsson A-Ch, Gilijam G, et al. An analysis of the inhibition of replication of HIV and MULV by some 3′-blocked analogs. Biochemical Pharmacology 38: 109–119, 1989
Beldekas JC, Levy EM, Black P, von Krogh G, Sandström E. In vitro effect of foscarnet on expansion of T-cells from people with LAS and AIDS. Lancet 2: 1128–1129, 1985
Bergdahl S, Sönnerborg A, Larsson A, Strannegård O. Declining levels of HIV p24 antigen in serum during treatment with foscarnet. Lancet 1: 1052, 1988
Besen LJ, Greene JB, Louie E, Seitzman P, Weinberg H. Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC. New England Journal of Medicine 318: 708, 1988
Bhalla K, Birkhofer M, Grant S, Graham G. The effect of recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) on 3′-azido-3′-deoxythymidine (AZT)-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cells. Experimental Hematology 17: 17–20, 1989
Biesert L, Suhartono H, Winkler I, Meichsner C, Hellsberg M, et al. Inhibition of HIV and virus replication by polysulphated polyoxylan: HOE/BAY 946, a new compound. AIDS 2: 449–457,1988
Billich S, Knoop M-T, Hansen J, Strop P, Sedalacek J, et al. Synthetic peptides as substrates and inhibitors of the human immune deficiency virus-1 protease. Journal of Biological Chemistry 263: 17905–17908, 1988
Blum MR, Liao SHT, Good SS, de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. American Journal of Medicine 85: 189–194, 1988
Brockmeyer NH, Kreuzfelder E, Mertins L, Chalabi N, Kirch W, et al. Immunomodulatory properties of cimetidine in ARC patients. Clinical Immunology and Immunopathology 48: 50–60, 1988
Broder S, Yarchoan R, Collins JM, Lane HC, Markham PD, et al. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi’s sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet 2: 627–629, 1985
Brodsky I, Strayer DR. Therapeutic potential of ampligen. American Family Physician 36: 253–256, 1987
Busch W, Brodt R, Ganser A, Helm EB, Stille W. Suramin treatment for AIDS. Lancet 2: 1247, 1985
Cacoub P, Deray G, Baumelou A, Le Hoang P, Rozenbaum W, et al. Acute renal failure induced by foscarnet: 4 cases. Clinical Nephrology 29: 315–318, 1988
Campoli-Richards DM, Sorkin EM, Heel RC. Inosine pranobex: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 32: 383–424, 1986
Carter WA, Strayer DR, Brodsky I, Lewin M, Pellegrino MG, et al. Clinical, immunological and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Lancet 1: 1286–1292, 1987
Chaisson RE, Leuther MD, Allain J-P, Nusinof-Lehrman S, Boone GS, et al. Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Archives of Internal Medicine 148: 2151–2153, 1988
Chandra A, Demirhan I, Araya SK, Chandra P. D-Penicillamine inhibits transactivation of human immunodeficiency virus type-1 (HIV-1) LTR by transactivator protein. Federation of European Biochemical Societies Letters 236: 282–286, 1988
Chandra P, Sarin PS. Selective inhibition of replication of the AIDS-associated virus HTLV-III/LAV by synthetic D-penicil-lamine. Drug Research 36: 184–186, 1986
Chang T-W, Hell RC. Ribavirin and inosiplex: a review of their present status in viral diseases. Drugs 22: 111–128, 1981
Chaudhary VK, Mizukami T, Fuerst TR, FitzGerald DJ, Moss B, et al. Selective killing of HIV infected cells by recombinant human CD4-pseudomonas exotoxin hybrid proretin. Nature 335: 369–372, 1988
Cheson BD, Levine AM, Mildvan D, Kaplan LD, Wolfe P, et al. Suramin therapy in AIDS and related disorders: report of the US working group. Journal of the American Medical Association 258: 1347–1351, 1987
Chou T-C, Talay P. Applications of the median-effect principle for the assessment of low-risk carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. In Harrap KR & Commors TA (Eds) New avenues in developmental cancer therapy, Bristol Meyers Cancer Symposia, Orlando, Florida, Academic Press, 1987
Chu CK, Schinazi RF, Arnold BH, Cannon DL, Doboszewski B, et al. Comparative activity of 2′,3′-saturated and unsaturated pyfimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells. Biochemical Pharmacology 37: 3543–3548, 1988
Clapham PR, Weber JN, Whithby D, Mclntosh K, Dalgleish AG, et al. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature 337: 368–370, 1989
Collins JM, Klecker RW, Yarchoan R, Lane HC, Fauci AS, et al. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. Journal of Clinical Pharmacology 26: 22–26, 1986
Cook DJ, Kelton JG, Stanisz AM, Collins SM. Somatostatin treatment for cryptosporidial diarrhea in a patient with the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine 108: 708–709, 1988
Crumpacker C, Bubley G, Lucey D, Hussey S, Conner J. Ribavirin enters cerebrospinal fluid. Lancet 2: 45–46, 1986
Dalgleish AG, Beverly PCL, Clapham PR, Crawford DH, Greaves MF, et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763–767, 1984
De Clercq E. Suramin: a potent inhibitor of reverse transcriptases. Cancer Letters 8: 9–22, 1979
De Clercq E. Specified targets for antiviral drugs. Biochemical Journal 205: 1–13, 1982
Deen KC, McDougal S, Inacker R, Folena-Wasserman G, Arthos J, et al. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Correspondence. Nature 331: 82–84, 1988
De Simone C, Ferrazzi M, Bitonti F, Falciaon M, Tzantzoglou S, et al. Pharmacokinetics of zidovudine and concomitant inosine-pranobex in AIDS patients. Immunopharmacology and Immunotoxicology 10: 437–441, 1988
de Wit R, Schattenkerk JKME, Boucher CAB, Bakker PJM, Veenhof KHN, et al. Clinical and virological effects of high-dose recombinant interferon alpha in disseminated AIDS-related Kaposi’s sarcoma. Lancet 2: 1214–1217, 1988
de Wolf F, Lange JMA, Goudsmit J, Cload P, de Gans J, et al. Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet 1: 373–376, 1988
Dormont D, Daveloose D, Yermanian P, Barre-Sinoussi FC, Lambert P, et al. Cellular and molecular mechanisms of antiretroviral effects of HPA 23. Cancer Detection and Prevention 12: 181–194, 1988
Dormont D, Spire B, Barre-Sinoussi F, Montagnier L, Chermann JC. Inhibition of the RNA dependent DNA polymerase of AIDS and SAIDS retroviruses by HPA-23 (ammonium-21-tungsto-9-antimoniate). Annales de l’Institut Pasteur-Virologie 136E: 75–83,1985
Dournon E, Matheron S, Rozenbaum W, Gharakhanian S, Michon C, et al. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 2: 1297–1302, 1988
Dubinsky RM, Dalakas M, Yarchoan R, Broder S. Follow-up of neuropathy from 2′,3′-dideoxycytidine. Lancet 1: 832, 1988
Duvic M, Rios A, Brewton GW. Remission of AIDS-associated psoriasis with zidovudine. Lancet 2: 627, 1987
Faber V, Dalgleish AG, Newell A, Malkovsky M. Inhibition of HIV replication in vitro by fusidic acid. Lancet 2: 827–828, 1987
Farthing CF, Dalgleish AG, Clark A, McClure M, Chanas A, et al. Phosphonoformate (Foscarnet): a pilot study in AIDS and ARC related complex. AIDS 1: 12–15, 1987
Feeney GFX, Frazer I. AIDS-associated psoriasis response to azidothymidine. Medical Journal of Australia 148: 155, 1988
Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine 317: 185–191, 1987
Fisher J, Ricard L, Weiss R. The structure of the heteropolytungstate (NH4) NaW21Sb9086-14H20: an inorganic cryptate. Journal of the American Chemistry Society 98: 3050–3052, 1976
Fisher RA, Bertonis JM, Meier W, Johnson VA, Costopoulos DS, et al. HIV infection blocked in vitro by recombinant soluble CD4. Correspondence. Nature 331: 76–78, 1988
Fleet GWJ, Karpas A, Dwek RA, Fellows LE, Tyms AS, et al. Inhibition of HIV replication by amino-sugar derivatives. Federation of European Biochemical Societies Letters 237: 128–132, 1988
Forester G. Profound cytopenia secondary to azidothymidine. Lancet 2: 772, 1987
Frankel AD, Cheng-Mayer C, Levy JA. Tat protein from human immunodeficiency virus forms a metal-linked dimer. Science 240: 70–73, 1988
Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proceedings of the National Academy of Sciences USA 83: 8333–8337, 1986
Furth PA, Kazakis A. Nail pigmentation changes associated with azidothymidine (AZT). Annals of Internal Medicine 107: 350, 1987
Gaub J, Pedersen C, Paulsen A-G, Mathiesen LR, Ulrich K, et al. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. AIDS 1: 27–33, 1987
Germain RN. Antigen processing and CD4+ cell depletion. Cell 54: 441–444, 1988
Gill PS, Rarick M, Brynes RK, Causey D, Loureiro C, et al. Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine 107: 502–505, 1987
Gorard DA, Henry K, Guilioff RJ. Necrotizing myopathy and zidovudine. Lancet 1: 1050, 1988
Gordon J, Ginsberg Th. Isoprinosine and NPT 15392: hypoxanthine-containing immunomodulators. Handbook of Experimental Pharmacology 85: 535–553, 1988
Gottlieb AA, Gottlieb MS, Scholes VE. Reconstitution of immune function in AIDS/ARC. Concepts in Immunopathology 4: 261–274, 1987a
Gottlieb MS, Wolfe P, Chafey S. Case report: response of AIDS-related thrombocytopenia to intravenous and oral azidothymidine (3′-azido-3′-deoxythymidine). AIDS Research and Human Retroviruses 3: 109–114, 1987b
Groopman JE, Mitsuyasu RT, DeLeo MJ, Oette DH, Golde DW. Effect of recombinant human granulocyte-macrophage colony stimulating factor on the myelopoiesis in the acquired immunodeficiency syndrome. New England Journal of Medicine 317: 593–598, 1987
Hammer S, Gillis JM. Synergistic activity of granulocyte-macrophage colony stimulating factor and 3′-azido-3′-deoxythymidine against human immunodeficiency virus in vitro. Antimicrobial Agents and Chemotherapy 31: 1046–1050, 1986
Hansen J, Schultze T, Meliert W, Moelling K. Identification and description of HIV-specific RNase H by monoclonal antibody. EMBO Journal 8: 239–243, 1988
Hargreaves M, Fuller G, Costello C, Gazzard B. Zidovudine overdose. Lancet 2: 509, 1988
Hart C, Schochetman G, Spira T, Lifson A, Moore J, et al. Direct detection of HIV RNA expression in seropositive subjects. Lancet 2: 596–599, 1988
Hartshorn KL, SandstrÖm EG, Neumeyer D, Paradis TJ, Chou TC, et al. Synergistic inhibition of human T-cell lymphotropic virus type III replication by phosphonoformate and alpha A-interferon. Antimicrobial Agents and Chemotherapy 30: 189–191, 1986
Hartshorn KL, Vogt MW, Chou TC, Blumberg R, Byington R, et al. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrobial Agents and Chemotherapy 31: 168–172, 1987
Haseltine WA. Replication and pathogenesis of the AIDS virus. Journal of Acquired Immune Deficiency Syndromes 1: 217–240, 1988
Hayashi S, Phadtare S, Zemlicka J, Matsukura M, Mitsuya H, et al. Adenallene and cytallene: acyclic nucleoside analogues that inhibit replication and cytopathic effect of human immunodeficiency virus in vitro. Proceedings of the National Academy of Sciences USA 85: 6127–6131, 1988
Helbert M, Fletcher T, Peddle B, Harris RJW, Pinching AJ. Zidovudine-associated myopathy. Correspondence. Lancet 2: 689–690, 1988a
Helbert M, Robinson D, Peddle B, Forster S, Kocsis A, et al. Acute meningo-encephalitis on dose reduction of zidovudine. Lancet 1: 1249–1252, 1988b
Heley A. Foscarnet infusion at home. Lancet 2: 1311, 1988
Helgstrand E, Eriksson B, Johansson NG, Lännero B, Larsson A, et al. Trisodium phosphonoformate, a new antiviral compound. Science 201: 819–821, 1978
Henry K, Chinnock BJ, Quinn RP, Fletcher CV, de Miranda P, et al. Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. Journal of the American Medical Association 259: 3023–3026, 1988
Herdewijn P, Balzarini J, Baba M, Pauwels R, van Aershot A, et al. Synthesis and anti-HIV activity of different sugar-modified purines and pyrimidines. Journal of Medical Chemistry 31: 2040–2048, 1988
Hirsch MS. Antiviral drug development for the treatment of human immunodeficiency virus infection. American Journal of Medicine 85 (Suppl. 2A): 182–185, 1988
Ho DD, Hartshorn K, Rota TR, Andrews CK, Kaplan JC, et al. Recombinant human interferon alpha-A suppresses HTLV III replication in vitro. Lancet 1: 602–604, 1985
Horwitz JP, Chua J, Noel M. Nucleosides. V. The monomesylates of l-(2′-deoxy-beta-D-lyxofuranosyl)thymidine. Journal of Organic Chemistry 29: 2076–2078, 1964
Hubbell HR. Synergistic antiproliferative effect of human interferons in combination with mismatched double-stranded RNA on human tumor cells. International Journal of Cancer 37: 359–365, 1986
Hussey RE, Richardson NE, Kowalski M, Brown NR, Chang H-C, et al. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Correspondence. Nature 331: 78–81, 1988
Hutchinsson V, Cummings JM. Low-dose oral interferon in a patient with AIDS. Lancet 2: 1530–1531, 1987
Hymes KB, Greene LB, Karpatkin S. The effect of azidothymidine on HIV-related thrombocytopenia. New England Journal of Medicine 318: 516–517, 1988
Interferon Alpha Study Group. A randomized placebo-controlled trial of recombinant human interferon alpha in patients with AIDS. Journal of Acquired Immune Deficiency Syndrome 1: 111–118, 1988
Ito M, Baba M, Sato A, Pauwels R, De Clercq E, et al. Inhibitory effect of dextran sulphate and heparin on the replication of the human immunodeficiency virus (HIV) in vitro. Antiviral Research 7: 361–367, 1987
Jackson GG, Paul DA, Falk LA, Rubenis M, Despotes JC, et al. Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT). Annals of Internal Medicine 108: 175–180, 1988b
Jackson GG, Perkins JT, Rubenis M, Paul DA, Knigge M, et al. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet 2: 647–652, 1988a
Jacobson MA, Crowe SD, Levy J, Aweeka F, Gamertoglio J, et al. Effect of foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. Journal of Infectious Diseases 158: 862–865, 1988
Jamesson BA, Rao PE, Kong LI, Hahn BH, Shaw GM, et al. Location and the chemical synthesis of binding site for HIV-1 on the CD4 protein. Science 240: 1335–1339, 1988
Jasmin C, Chermann J-C, Herve G, Teze A, Souchay P, et al. In vivo inhibition of murine leukaemia and sarcoma viruses by the heteropoly-anion 5-tungsto-2-antimonate. Journal of the National Cancer Institute 53: 469–474, 1974
Jentsch KD, Hunsmann G, Hartmann H, Nickel P. Inhibition of human immunodeficiency virus type I reverse transcriptase by suramin related compounds. Journal of General Virology 68: 2183–2192, 1987
Johnson MA, Ahluwalia G, Connelly MC, Cooney DA, Broder S, et al. Metabolic pathway for the activation of the antiretroviral agent 2′,3′-dideoxyadenosine in human lymphoid cells. Journal of Biological Chemistry 263: 15354–15357, 1988
Johnson VA, Walker BD, Barlow MA, Paradis TJ, Chou T-C, et al. Synergistic inhibition of human immunodeficiency virus type 1 and type 2 replication by castanospermine and 3′-azido-3′-thymidine. Antimicrobial Agents and Chemotherapy 33: 53–57, 1989
Kaplan MH, Sadick NS, Wieder J, Farber BF, Neidt G. Anti-psoriatic effects of zidovudine in human immunodeficiency virus-associated psoriasis. Journal of the American Academy of Dermatology 20: 76–82, 1989
Karpas A, Hill F, Youle M, Cullen V, Gray J, et al. Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proceedings of the National Academy of Sciences 85: 9234–9237, 1988
Klecker RW, Collins JM, Yarchoan R, Thomas R, Jenkins JF, et al. Plasma and cerebrospinal fluid pnarmacokinetics of 3′-azido-3′deoxythymidine: a novel pyrimidine analogue with potential application for the treatment of patients with AIDS and related diseases. Clinical Pharmacological Therapy 41: 407–412, 1987
Kornhouser RH, Petty BG, Chan DA. Pharmacokinetics of intravenous HPA 23. Abstract no. 1098, 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1986
Kotler M, Katz RA, Danho W, Leis J, Skalka M. Synthetic peptides as substrates and inhibitors of a retroviral protease. Proceedings of the National Academy of Sciences USA 85: 4185–4189, 1988
Kuchino Y, Nishimura S, Schröder HC, Rottman M, Muller WG. Selective inhibition of formation of suppressor glutamine tRNA in Moloney Murine leukaemia virus infected NIH-3T3 cells by avarol. Virology 165: 518–526, 1988
Lane HC, Kovacs JA, Feinberg J, Herpin B, Davey L, et al. Anti-retroviral effects of interferon-α in AIDS-associated Kaposi’s sarcoma. Lancet 2: 1218–1222, 1988
Lang J-M, Touraine J-L, Trepo C, Choutet P, Kirstetter M, et al. Randomised, double-blind placebo-controlled trial of ditiocarb sodium (‘Imuthiol’) in human immunodeficiency virus infection. Lancet 2: 702–706, 1988
Lange P, Sönnichsen N. Beeinflussung der HIV-Infection durch Disulfiram. Zeitschrift für Klinische Medizin 43: 1439, 1988
Langtry HD, Campoli-Richards DM. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 37: 408–450, 1989
Laporte JPH, Meyohas MC, Eliaszewicz M, Najman A, Frottier J, et al. Adjonction d’HPA à la ciclosporine dans traitement des purpuras thrombocytopeniques des sujets HIV positif. Pathologie Biologie 35: 870–872, 1987
Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Sci-ence 243: 1731–1734, 1989
Laskin OL, Longstreth JA, Hart CC, Scavuzzo D, Kaiman CM, et al. Ribavirin disposition in high risk patients for acquired immunodeficiency syndrome. Clinical Pharmacology and Therapeutics 41: 546–555, 1987
Laurence J, Kulkosky J, Friedman SM, Posnett DN, Ts’O POP. Polyl.polyC12U-mediated inhibition of loss of alloantigen responsiveness and viral replication in human CD4+ cell clones exposed to human immunodeficiency virus in vitro. Journal of Clinical Investigation 80: 1631–1639, 1987
Levine AM, Gill PS, Cohen J, Hawkins JG, Formenti SC, et al. Suramin antiviral therapy in the acquired immunodeficiency syndrome: clinical, immunologic and virologic results. Annals of Internal Medicine 105: 32–37, 1986
Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimbukuro JM, et al. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 225: 840–842, 1984
Lifson JD, Hwang KM, Nara PL, Fraser B, Padgett M, et al. Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. Science 241: 712–716, 1988
Liu MA, Liu T. Effect of recombinant soluble CD4 on human peripheral blood lymphocyte responses in vitro. Journal of Clinical Investigation 82: 2176–2180, 1988
Lowy DR. Transformation and oncogenesis: retroviruses. In Fields BN (Ed.) Virology, Raven Press, New York, 1985
Lucas C, Frie SW, Capon DJ, Chamow SM, Mordentel JJ. Pharmacokinetics of recombinant soluble human CD4. Abstract no. G425, UCLA Symposium on Human Retroviruses, Tamarron 1989. Journal of Cellular Biochemistry(Suppl. 13B):304, 1989
Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, et al. Phosphorothioate analogues of oligodeoxynucleotides: inhibitors of replication and cytopathic effects on human immunodeficiency virus. Proceedings of the National Academy of Sciences USA 84: 7706–7710, 1987
McCormick JB, Getchell JP, Mitchell SW, Hicks DR. Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T-lymphocytes. Lancet 2: 1367–1369, 1984
Melamed AJ, Müller RJ, Gold JWM, Campbell SW, Kleinberg ML, et al. Possible zidovudine-induced hepatotoxicity. Journal of the American Medical Association 258: 2063, 1988
Meruelo D, Lavie G, Lavie D. Therapeutic agents with dramatic antiretroviral activity and little toxicity at affective doses: aromatic polycyclic diones hypercin and pseudohypercin. Proceedings of the National Academy of Sciences USA 85: 5230–5234,1988
Michaelis B, Levy J. HIV replication can be blocked by recombinant interferon beta. AIDS 3: 27–31, 1988
Mir N, Costello C. Zidovudine and bone marrow. Lancet 2: 1195–1196, 1988
Mitchell WM, Montefiori DC, Robinson WE, Strayer DR, Carter WA. Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in vitro inhibition of human immunodeficiency virus. Lancet 1: 890–892, 1987
Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/ lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′- dideoxynucleosides. Proceedings of the National Academy of Sciences USA 83: 1911–1915, 1986
Mitsuya H, Broder S. Strategies for antiviral therapy in AIDS. Nature 325: 773–778, 1987
Mitsuya H, Jarrett RF, Matsukura M, Veronese FDM, DeVico AL, et al. Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2′,3′-dideoxynucleosides in vitro. Proceedings of the National Academy of Sciences USA 84: 2033–2037, 1987
Mitsuya H, Looney DJ, Kuno S, Ueno R, Wong-Staal F, et al. Dextran sulphate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 240: 646–649, 1988
Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, et al. Suramin protection of T-cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 226: 172–174, 1984
Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, et al. 3′-Azido-3′-deoxythymidine (BW A509U): a new antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus III/lymphadenopathy associated virus in vitro. Proceedings of the National Academy of Sciences USA 82: 7096–7100, 1985
Montefiori DC, Mitchell WM. Antiviral activity of mismatched double-stranded RNA against human immunodeficiency virus. Proceedings of the National Academy of Sciences USA 84: 2985–2989, 1987
Montefiori DC, Robinson WE, Mitchell WM. Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type-1. Proceedings of the National Academy of Sciences 85: 9248–9252, 1988
Moskowitz BL, the HPA-23 Cooperative Study Group. Clinical trial of tolerance of HPA-23 in patients with acquired immune deficiency syndrome. Antimicrobial Agents and Chemotherapy 32: 1300–1303, 1988
Muller WEG, Renneisen K, Kreuter MH, Schröder HC, Winkler I. The D-mannose-specific lection from gerardia savaglia blocks binding of human immunodeficiency virus type I to H9 cells and human lymphocytes in vitro. Journal of Acquired Immune Deficiency Syndromes 1: 453–458, 1988a
Muller WEG, Schröder HC, Reuter P, Sarin PS, Hess G, et al. Inhibition of expression of natural UAG suppressor glutamine tRNA in HIV-infected human H9 cells in vitro by avarol. AIDS Research and Human Retroviruses 4: 279–286, 1988b
Nightingale S. Retrovir approved. Journal of the American Medical Association 257: 2403, 1987
Öberg B. Antiviral therapy. Journal of Acquired Immune Deficiency Syndromes1: 257–266, 1988
Ostertag W, Roesler G, Krieg CJ, Kind J, Cole T, et al. Induction of endogenous virus and of thymidine kinase by bromodeoxuridine in cell cultures transformed by Friend virus. Proceedings of the National Academy of Sciences USA 71: 4980–4985, 1974
Parks WP, Parks ES, Fischl MA, Leuther MD, Allain JP, et al. HIV-1 inhibition by azidothymidine in a concurrently randomized placebo-controlled trial. Journal of Acquired Immune Deficiency Syndromes 1: 125–130, 1988
Perno C-F, Yarchoan R, Cooney DA, Hartman NR, Gartner S, et al. Inhibition of human immunodeficiency virus (HIV-1/ HTLV-IIIBa-L) replication in fresh and cultured peripheral blood monocytes/maCTophages by azidothymidine and related 2,3′-dideoxynucleotides. Journal of Experimental Medicine 168: 1111–1125,1988
Perno C-F, Yarchoan R, Cooney DA, Hartman NR, Mitsuya H, et al. Granulocyte-macrophage stimulating factor (GM-CSF) potentiates viral production in monocyte macrophages yet enhances antiviral activity of AZT and cogeners. Abstract no. G438, UCLA Symposium on Human Retroviruses, Tamarron, 1989. Journal of Cellular Biochemistry (Suppl. 13B): 308, 1989
Perth CB, Hill JM, Ruff ML, et al. Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibits human immunodeficiency virus receptor binding and T-cell infectivity. Proceedings of the National Academy of Sciences USA 83: 9254–9258, 1986
Pickus OB. Overdose of zidovudine. New England Journal of Medicine 318: 1206, 1988
Pincus S, Wehrly K, Chesebro B. Treatment of HIV tissue culture infections with antibody-ricin A chain conjugates. Abstract no. G439, UCLA Symposium on Human Retroviruses, Tamarron, 1989. Journal of Cellular Biochemistry (Suppl. 13B):309, 1989
Pizzo PA, Eddy J, Falloon J, Balis FM, Murphy RF, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with asymptomatic HIV infection. New England Journal of Medicine 319: 889–896, 1988
Pompidou A, Delsaux MC, Telvi L, Mace B, Coutance F, et al. Isoprinosine and imutiol: two potentially active compounds in patients with AIDS related complex. Cancer Research 45 (Suppl.): 4671, 1985
Popovic H, Sarngadharan MG, Read E, Gallo RC. Detection, isolation and continuous production of a cytopathic retrovirus (HTLV-III) from patients with AIDS and pre-AIDS. Science 224: 479–500, 1984
Reiss P, Lange JMA, Boucher CA, Danner SA, Goudsmit J. Resumption of HIV antigen production during continuous zidovudine treatment. Lancet 1: 421, 1988
Richman DD, Andrews J, AZT Collaborating Group. Results of continuous monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection. Journal of the American Medical Association 85 (Suppl. 2A): 208–213, 1988
Richman DD, Fischl M, Grieco MH, Gottlieb MS, Volberding PA, et al. The toxicity of azidothymidine in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine 317: 192–197, 1987a
Richman DD, Kornbluth RS, Carson DA. Failure of dideoxynucleosides to inhibit human immunodeficiency virus infection in cultured human macrophages. Journal of Experimental Medicine 166: 1144–1149, 1987b
Roberts DE, Bergman SM, Nakasato S, Wyle FA, Wishnow RM, et al. Effect of lithium carbonate on zidovudine-associated neutropenia in the acquired immunodeficiency syndrome. American Journal of Medicine 85: 428–431, 1988
Roberts RB, Laskin OL, Laurence J, Scavuzzo D, Murray HW, et al. Ribavirin pharmacodynamics in high risk patients for acquired immunodeficiency syndrome. Clinical Pharmacology and Therapeutics 42: 365–373, 1987
Routy JP, Prajs E, Blanc AP, Drony S, Moriceau M, et al. Seizure after zidovudine overdose. Lancet 1: 384–385, 1988
Rouvroy D, Bogaerts J, Habyarimana J-B, van der Perre R. Short-term results with suramin for AIDS-related conditions. Lancet 1: 878–879, 1985
Rozenbaum W, Dormont D, Spire B, Vilmer E, Gentilini M, et al. Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome. Lancet 1: 450–451, 1985
Ruff MR, Hallberg PL, Jill JM, Pert C. Peptide T(4–8) is the core HIV envelope sequence required for CD4 receptor attachment. Lancet 2: 751, 1987
Ruzicka T, Fröschl M, Hohenleutner U, Holzmann H, Braun-Falco O. Treatment of HIV-induced retinoid resistant psoriasis with zidovudine. Lancet 2: 1469–1470, 1987
Sandström EG, Kaplan JC. Antiviral therapy in AIDS. Drugs 34: 372–390, 1987
Sandström EG, Kaplan JC, Byington R, Hirsch MS. Inhibition of human T-cell lymphotropic virus type III by phosphonoformate. Lancet 2: 1480–1482, 1985
Sarin PS, Gallo RC, Scheer DI, Crews F, Lippa AS. Effects of a novel compound (AL721) in HTLV-III infectivity in vitro. Correspondence. New England Journal of Medicine 313: 1289–1290, 1985
Sarin PS, Sun D, Thornton A, Muller WEG. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone. Journal of the National Cancer Institute 78: 663–666, 1987
Schinazi RF, Cannon DL, Arnold BH, Martino-Saltzman D. Combinations of isoprinosine and 3′-azido-3′-thymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 32: 1784–1787, 1988
Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, et al. Neuropsychological outcome of zidovudine (AZT) treatment in patients with AIDS and AIDS-related complex. New England Journal of Medicine 319: 1573–1578, 1988
Schröder HC, Sarin PS, Rottman M, Wegner R, Maidhof A, et al. Differential modulation of host cell and HIV gene expression by combination of avarol and AZT. Biochemical Pharmacology 37: 3947–3952, 1988
Schulof RS, Scheib R, Parenti D, Simon GL, DiGiota RA, et al. Treatment of HTLV III/LAV-infected patients with D-penicillamine. Drug Research 36(II): 1531–1534, 1986
Shannon WM. Selective inhibition of RNA viruses replication in vitro and evaluation of candidate antiviral agents in vivo. Annals of the New York Academy of Sciences 284: 472–507, 1977
Siciliano RF, Lawton T, Knall RW, Berman P, Gregory T, et al. Analysis of host-virus interactions in AIDS withg anti-gp l20 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ depletion. Cell 54: 561–575, 1988
Sjöwall J, Karlsson A, Ogenstad S, Sandström E, Saarimäki M. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clinical Pharmacology and Therapeutics 44: 65–73, 1988
Skinner MA, Matthews TJ, Greenwell TK. AZT inhibits HIV-1 replication in monocytes. Journal of Acquired Immune Deficiency Syndromes 1: 162–164, 1988
Smith DH, Byrn R, Marsters SA, Gregory T, Groopman JE, et al. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 238: 1704–1707, 1987
Sodrosky J, Kowalski M, Dorfman T, Basiripour L, Rosen C, et al. HIV-CD4 interaction not inhibited by synthetic octapeptides. Lancet 1: 1428–1429, 1987
Sommadossi J-P, Carlisle R, Schinazi RF, Zhou Z. Uridine reverses the toxicity of 3′-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of retroviral activity. Antimicrobial Agents and Chemotherapy 32: 997–1001, 1988
Spear JB, Benson CA, Pottage JC, Paul DA, Landay AL, et al. Rapid rebound of serum human immunodeficiency virus! antigen after discontinuing zidovudine therapy. Journal of Infectious Diseases 158: 1132–1133, 1988a
Spear JB, Kessler HA, Nusinoff-Lehrman S, de Miranda P. Zidovudine overdose. Annals of Internal Medicine 109: 76–77, 1988b
Staszewski S, Rehmet S, Odewald J, Gottstein A, Helm EB. Over-dosage of zidovudine. Lancet 1: 385, 1989
Sundquist B, Lanier E. Phosphonoformate inhibition of visna virus replication. Journal of Virology 30: 847–851, 1978
Sundquist B, Öberg B. Phosphonoformate inhibits reverse transcriptase. Journal of General Virology 45: 273–281, 1979
Sunkara PS, Bowlin TL, Liu PS, Sjoersma A. Antiretroviral activity of castanospermine and deoxynoijrimycin, specific inhibitors of glycoprotein processing. Biochemical and Biophysical Research Communications 148: 206–210, 1987
Surbonne A, Yarchoan R, McAtee N, Blum MR, Maha M, et al. Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3′-azido-2′,3′- dideoxythymidine (azidothymidine or zidovudine) and acyclovir. Annals of Internal Medicine 108: 534–540, 1988
Swiss Group for Clinical Studies on the Acquired Immunodeficiency Syndrome. Zidovudine for the treatment of thrombo-cytopenia associated with human immunodeficiency virus (HIV). Annals of Internal Medicine 109: 718–721, 1988
Tartaglione TA, Collier AC. Development of antiviral drugs for the treatment of human immunodeficiency virus infection. Drug Reviews 6: 927–940, 1987
Terasaki T, Pardridge WM. Restricted transport of 3′-azido-3′-deoxythymidine and dideoxynucleotides through the blood-brain barrier. Journal of Infectious Diseases 158: 630–632, 1988
Till MA, Ghetie V, Gregory T, Patzer EJ, Porter JP, et al. HIV-infected cells are killed by rCD4-ricin A chain. Science 242: 1166–1168, 1989
Traunecker A, Luke W, Karjalainen K. Soluble CD4 neutralizes human immunodeficiency virus type 1. Correspondence. Nature 331: 84–86, 1988
Tsang KY, Tangnavarad K, Solomon S, Bekesi JG. Modulation of T-and B-cell functions by isoprinosine in homosexual subjects with prodromata and in patients with acquired immune deficiency syndrome (AIDS). Journal of Clinical Immunology 4: 469–478, 1984
Tyms AS, Berrie EM, Ryder TA, Nash RJ, Hegarty MP, et al. Castanospermine and other plant alkaloid inhibitors of glucosidase activity block growth of HIV. Lancet 2: 1025–1026, 1987
Ueno R, Kuno S. Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine. Lancet 1: 1379, 1987
Vince R, Hua M, Brownell J, Daluge S, Lee F, et al. Potent and selective activity of a new carboxylic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro. Biochemical and Biophysical Research Communications 156: 1046–1053, 1988
Vittecoq D, Woerle R, Barre-Sinoussi F, Chermann JC, et al. Reverse transcriptase activity (RTA) in lymphocyte cultures of HIV infected patients receiving short treatments of HPA-23: a biological evaluation. Biomedicine and Pharmacotherapy 42: 35–40, 1988
Vogt MJ, Durno AG, Chou T-C, Coleman LA, Paradis TJ, et al. Synergistic interaction of 2′,3′-dideoxycytidine and recombinant interferon alpha A on the replication of human immunodeficiency virus. Journal of Infectious Diseases 158: 378–385, 1988
Vogt MW, Hartshorn K, Furman PA, Chou TC, Fyfe JA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235: 1376–1379, 1987
Wagner WH. Hoe/Bay 946: a new compound with activity against the AIDS virus. Arzneimittel-Forschung 39: 112–113, 1989
Wainberg MA, Dascal A, Blain N, Fitz-Gibbon L, Boulerice F, et al. The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1. Blood 72: 1904–1910, 1988
Walker BD, Kowalski M, Goh WC, Kozarsky K, Krieger M, et al. Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proceedings of the National Academy of Sciences USA 84: 8120–8124, 1987
Walker RE, Parker RI, Ko vacs JA, Masur H, Lane C, et al. Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi’s sarcoma treated with zidovudine. Annals of Internal Medicine 108: 372–376
Watanabe M, Reimann KA, DeLong PA, Liu T, Fisher RA, et al. Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques. Nature 337: 267–270, 1989
Wallace JI, Bekesi JG. A double-blind clinical trial of the effects of inosine pranobex in immunodepressed patients with prolonged generalized lymphadenopathy. Clinical Immunology and Immunopathology 39: 179–186, 1986
Wetterberg L, Alexius B, Sääf J, Sonnerborg A, Britton S, et al. Peptide T in treatment of AIDS. Lancet 1: 159, 1987
Witkowski JT, Robins RK, Sidwell RW, Simon LN. Design, synthesis and broad spectrum antiviral activity of 1-a-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. Journal of Medicinal Chemistry 15: 1150–1154, 1972
Yarchoan R, Berg G, Brouwers P, Fischl M, Spitzer AR, et al. Response of human immunodeficiency virus associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet 1: 132–137, 1987
Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1: 575–580, 1986
Yarchoan R, Perno CF, Thomas RV, Klecker RW, Allain J-P, et al. Phase I studies of 2′3′-dideoxythymidine in severe human immunodeficiency virus infection as a single agent or alternating with zidovudine (AZT). Lancet 1: 76–81, 1988b
Yarchoan R, Thomas RV, Grafman J, Wichman A, Dalakas M, et al. Long-term administration of 3′azido-2′3′-dideoxythymidine to patients with AIDS-related neurological disease. Annals of Neurology 23: S82–S85, 1988a
Yarchoan R, Thomas RV, Mitsuya H, Perno C-F, Pluda JM, et al. Initial clinical studies of 2′,3′-dideoxyadenosine (ddA) and 2′,3′-dideoxyinosine (ddI) in patients with AIDS or AIDS-related complex. Abstract no. G451, UCLA Symposium on Human Retroviruses, Tamarron, 1989. Journal of Cellular Biochemistry (Suppl. 13B): 313, 1989
Yokota Y, Wakaki Y, Watanabe Y, Mine Y. Inhibitory effect of FK-565 alone and in combination with zidovudine on retroviral infection by Friend leukemia virus in mice. Journal of Antibiotics 61: 1479–1487, 1988
Zaia JA, Rossi JJ, Murakawa GJ, Spallone PA, Stephens DA, et al. Inhibition of human immunodeficiency virus by using an oligonucleoside methylphosphonate targeted to the tat-3 gene. Journal of Virology 62: 3914–3917, 1988
Zolla-Pazner S, Pinter A, Mizuma H. Potential use of serotherapy in the prevention and treatment of infection with the human immunodeficiency virus. Journal of Virological Methods 17: 45–53,1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sandström, E. Antiviral Therapy in Human Immunodeficiency Virus Infection. Drugs 38, 417–450 (1989). https://doi.org/10.2165/00003495-198938030-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198938030-00005